Get the Daily Brief
Latest Biotech News
Nanovaccines: engineered approach to hepatocellular carcinoma immunotherapy
Researchers reported engineered nanovaccine platforms aimed at hepatocellular carcinoma (HCC) immunotherapy, describing design features that improve antigen presentation and immune stimulation in...
Smart AAVs respond to tumor microenvironment – precision delivery
A new design framework for adeno‑associated virus (AAV) vectors enables dynamic responses to tumor microenvironment cues, improving tumor targeting and intratumoral delivery in preclinical models....
SpatialBench... agents face real‑world spatial biology test
SpatialBench introduced a benchmark suite of 146 verifiable problems drawn from authentic spatial biology workflows to evaluate agent‑style models on spatial assay analysis. The benchmark spans...
AI prognostics in gastric cancer — models refine risk, therapy selection
Deep learning models developed for gastric cancer prognosis and immunotherapy response prediction showed improved risk stratification using digital pathology. The study, published in the Journal...
CMS unveils voluntary payment model to expand Medicare GLP‑1 access
CMS launched a voluntary payment model designed to expand Medicare coverage of GLP‑1 weight‑loss drugs by testing alternative payment and reimbursement structures for participating plans and...
FDA approves Yartemlea: first therapy for fatal stem‑cell transplant complication
The FDA granted approval to Omeros’s complement inhibitor Yartemlea for treating a severe, potentially fatal complication of hematopoietic stem cell transplants, marking the first approved therapy...
J&J drops eczema asset — $1.25 billion acquisition yields failure
Johnson & Johnson announced it is discontinuing development of the eczema candidate JNJ‑5939 (NM26) acquired in a $1.25 billion deal, after the drug failed to meet efficacy thresholds in a Phase 2...
CAR‑T vs bispecifics... meta‑analysis compares outcomes in relapsed B‑cell NHL
A new meta‑analysis compared CAR‑T therapies with bispecific antibodies for relapsed or refractory indolent B‑cell non‑Hodgkin’s lymphomas, synthesizing outcomes across trials to clarify efficacy...
Potent antibodies target Marburg and Ravn: cross‑neutralizers discovered
Researchers reported discovery of a class of potent, cross‑neutralizing monoclonal antibodies that neutralize the Marburg virus and the related Ravn virus, according to a study published in npj...
Tumor‑responsive AAVs enable precise therapy: smart vectors breach TME
Scientists unveiled an intelligent design framework for adeno‑associated virus (AAV) vectors that dynamically respond to tumor microenvironment cues to improve tumor targeting and intratumoral...
SpatialBench... benchmark for agents on real spatial biology tasks
SpatialBench, introduced in a new paper, offers a suite of 146 verifiable problems drawn from real spatial biology workflows across five platforms (MERFISH, Seeker, Visium, Xenium, ATLASxomics...
Nanovaccines target HCC: new routes for liver cancer immunotherapy
Researchers presented nanovaccine platforms engineered to prime immune responses against hepatocellular carcinoma (HCC), detailing antigen delivery, adjuvant selection and tumor‑site activation...
CAR‑T neurotoxicity... fresh findings on mechanisms and management
A recent report consolidated advances in understanding CAR‑T associated neurotoxicity, outlining cellular and molecular mechanisms implicated in immune effector cell‑associated neurotoxicity...
Targeted protein degradation: therapeutic promise and cross‑species impacts
A broad review examined targeted protein degradation technologies and their implications for human health and non‑human species, mapping therapeutic opportunities and potential ecological or...
CMS unveils Medicare GLP-1 payment model: voluntary pilot to expand access
CMS launched a voluntary Medicare payment model designed to broaden coverage of GLP‑1 therapies for weight loss and diabetes. The agency framed the pilot as a mechanism to lower beneficiary...
FDA approves Yartemlea: first drug for deadly stem‑cell transplant complication
The FDA granted approval to Omeros’s complement inhibitor Yartemlea as the first therapy for a severe, potentially fatal complication arising after hematopoietic stem‑cell transplantation. The...
SpatialBench... a real‑world benchmark to stress‑test biology AI agents
Researchers introduced SpatialBench, a suite of 146 verifiable problems drawn from authentic spatial biology workflows to benchmark AI agents on real analysis tasks. The dataset spans five...
Tumor‑responsive AAVs: engineered vectors that sense the microenvironment
A research team disclosed an intelligent design framework for adeno‑associated virus (AAV) vectors that selectively activate within the tumor microenvironment (TME). The engineered AAVs...
Nanovaccines target HCC: nanotechnology-based immunotherapy advances
Researchers reported nanovaccine platforms designed to stimulate anti‑tumor immunity against hepatocellular carcinoma (HCC). The nanovaccines package tumor antigens and adjuvants into nanoparticle...
Dual IGF‑1R and autophagy blockade halts metastasis: a combinatorial strategy
A 2026 study demonstrated that simultaneous inhibition of IGF‑1 receptor signaling and autophagy suppresses colorectal cancer metastasis in preclinical models. Mahgoub and colleagues showed the...